PALOMA-2: Palbociclib Plus Letrozole in ER-Positive, HER2-Negative Advanced Breast Cancer

Primary endpoint (Investigator-assessed PFS): 24.8 vs 14.5 months — HR 0.58 (95% CI 0.46–0.72; P<0.001) Key secondary (PFS by central review): 30.5 vs 19.3 months — HR 0.65 (95% CI 0.51–0.84; P=0.001) Key secondary (ORR, measurable disease): 55.3% vs 44.4% — OR 1.55 (95% CI 1.05–2.28; P=0.03) Key secondary (CBR, all patients): 84.9% vs 70.3% — OR 2.39 (95% CI 1.58–3.59; P<0.001) Safety signal: Neutropenia (grade 3 or 4: 66.4% vs 1.4%); febrile neutropenia 1.8%

📱 Clinic quick reference: Mobile version — save for point-of-care use

Clinical Bottom Line

PALOMA-2 demonstrated that adding palbociclib to letrozole as first-line therapy for postmenopausal women with ER-positive, HER2-negative advanced breast cancer significantly extends progression-free survival compared with letrozole alone. The benefit was consistent across all prespecified subgroups, including patients with visceral disease, those with newly diagnosed metastatic disease, and those with prior adjuvant hormonal therapy.

This trial was the confirmatory phase 3 study following the accelerated approval of palbociclib based on the phase 2 PALOMA-1 trial, and it cemented palbociclib plus letrozole as a first-line standard of care for this population. Together with MONALEESA-2 (ribociclib) and MONARCH 3 (abemaciclib), PALOMA-2 established CDK4/6 inhibitors plus aromatase inhibitor as the preferred first-line endocrine-based approach for HR-positive, HER2-negative advanced breast cancer. Overall survival data were immature at this publication; subsequent analyses have since reported mature OS results.

The dominant toxicity is neutropenia — grade 3 or 4 neutropenia occurred in two-thirds of patients. However, febrile neutropenia was rare, and neutropenia was managed with the built-in 1-week-off dosing schedule and dose reductions. No treatment-related deaths occurred in the palbociclib arm. The manageable safety profile, combined with the 3-weeks-on/1-week-off oral schedule, makes this a practical outpatient regimen.

Trial Overview

Study Design

• Trial name and registration: PALOMA-2 (NCT01740427)
• Design: Phase 3, double-blind, placebo-controlled, randomized
• Randomization: 2:1 (palbociclib–letrozole : placebo–letrozole), stratified by site of disease (visceral or nonvisceral), disease-free interval from end of adjuvant/neoadjuvant treatment to recurrence (newly metastatic, ≤12 months, or >12 months), and status with respect to prior adjuvant/neoadjuvant hormonal therapy (prior receipt or no receipt)
• Setting: First-line treatment for ER-positive, HER2-negative advanced breast cancer in postmenopausal women
• Enrollment period and sites: February 2013 through July 2014 at 186 sites in 17 countries

Note: One interim analysis was planned after approximately 65% of total events, using a prespecified Haybittle–Peto efficacy boundary with an alpha level of 0.000013. The primary analysis log-rank test was stratified by the presence or absence of visceral disease only.

Mechanism of Action

Palbociclib is an oral, selective, reversible inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By inhibiting CDK4/6, palbociclib prevents phosphorylation of the retinoblastoma protein, blocking G1-to-S cell cycle transition in ER-positive breast cancer cells. It is administered on a 3-weeks-on/1-week-off schedule, which allows for hematologic recovery during the off-treatment week [2].

Patient Population

• Key eligibility: Postmenopausal women with ER-positive, HER2-negative advanced breast cancer; no prior systemic therapy for advanced disease; prior adjuvant/neoadjuvant nonsteroidal aromatase inhibitor allowed unless recurrence occurred during or within 12 months of therapy; adequate organ function; ECOG PS 0–2; measurable disease per RECIST v1.1 or bone-only disease. Key exclusions: advanced, symptomatic visceral spread at risk for life-threatening complications.
• Biomarker selection: ER-positive, HER2-negative
• Sample size flow: 666 randomized (444 palbociclib–letrozole, 222 placebo–letrozole) → 666 ITT and safety population

Baseline Characteristics

Baseline characteristics were well balanced between groups. Approximately half had visceral disease, and approximately one-third were newly diagnosed with metastatic breast cancer. Over half had received prior adjuvant hormonal therapy. There was a slight imbalance in ECOG PS distribution (57.9% PS 0 in palbociclib vs 45.9% in placebo), though the overall balance was acceptable.

Treatment Protocol

Experimental Arm: Palbociclib–Letrozole (n=444 randomized; safety population n=444)

Palbociclib 125 mg per day orally in 4-week cycles (3 weeks on/1 week off) plus letrozole 2.5 mg per day orally (continuous)

• Dose and schedule: Palbociclib 125 mg/day, days 1–21 of each 28-day cycle; letrozole 2.5 mg/day continuously
• Treatment duration: Until objective disease progression per RECIST v1.1, unacceptable toxic effects, or withdrawal of consent
• Median treatment duration: Not reported in this publication
• Median relative dose intensity: 93% for palbociclib and 100% for letrozole

At the data cutoff, 199 patients (44.8%) were still receiving palbociclib plus letrozole. Disease progression led to discontinuation in 172 patients (38.7%).

Control Arm: Placebo–Letrozole (n=222 randomized; safety population n=222)

Matching placebo in 4-week cycles (3 weeks on/1 week off) plus letrozole 2.5 mg per day orally (continuous)

• Dose and schedule: Matching placebo, days 1–21 of each 28-day cycle; letrozole 2.5 mg/day continuously
• Treatment duration: Until objective disease progression per RECIST v1.1, unacceptable toxic effects, or withdrawal of consent
• Median treatment duration: Not reported in this publication
• Median relative dose intensity: 100% for both placebo and letrozole

At data cutoff, 61 patients (27.5%) were still receiving placebo plus letrozole. Disease progression led to discontinuation in 125 patients (56.3%).

Crossover between study groups was not allowed. Subsequent therapy rates were not reported in this publication.

Efficacy Outcomes

Primary Endpoint: Investigator-Assessed Progression-Free Survival

Definition: Time from randomization to radiologically confirmed disease progression according to RECIST v1.1, or death during the study

Analysis population: Intention-to-treat (N=666)

Statistical method: Prespecified log-rank test stratified by presence or absence of visceral disease; Kaplan–Meier method for median estimates; Cox proportional-hazards models for hazard ratios

Median follow-up: 23 months

Palbociclib–Letrozole: Median PFS 24.8 months (95% CI 22.1 to not estimable) — 194 events in 444 patients (43.7%) Placebo–Letrozole: Median PFS 14.5 months (95% CI 12.9–17.1) — 137 events in 222 patients (61.7%) Comparison: HR 0.58 (95% CI 0.46–0.72; two-sided P<0.001)

A total of 331 PFS events had occurred by the data cutoff; 347 events were planned for the final analysis with 90% power to detect HR 0.69.

Key Secondary Endpoints

Overall Survival

Formally tested: Yes (planned hierarchically)

Data on overall survival were immature at the time of this analysis of the primary endpoint. The final overall survival analysis was planned when a total of 390 deaths occur per protocol and in agreement with regulatory agencies. No median OS, HR, or p-value was reported at this analysis.

Objective Response Rate — All Randomly Assigned Patients

Analysis population: Intention-to-treat (N=666) Formally tested: Yes

Palbociclib–Letrozole: ORR 42.1% (95% CI 37.5–46.9) Placebo–Letrozole: ORR 34.7% (95% CI 28.4–41.3) Comparison: OR 1.40 (95% CI 0.98–2.01; P=0.06)

The ORR difference in the all-randomized population was not statistically significant.

Objective Response Rate — Patients with Measurable Disease

Analysis population: Patients with measurable disease (palbociclib n=338; placebo n=171) Formally tested: Yes

Palbociclib–Letrozole: ORR 55.3% (95% CI 49.9–60.7) Placebo–Letrozole: ORR 44.4% (95% CI 36.9–52.2) Comparison: OR 1.55 (95% CI 1.05–2.28; P=0.03)

Clinical Benefit Response — All Randomly Assigned Patients

Analysis population: Intention-to-treat (N=666) Formally tested: Yes

Palbociclib–Letrozole: CBR 84.9% (95% CI 81.2–88.1) Placebo–Letrozole: CBR 70.3% (95% CI 63.8–76.2) Comparison: OR 2.39 (95% CI 1.58–3.59; P<0.001)

Clinical Benefit Response — Patients with Measurable Disease

Analysis population: Patients with measurable disease Formally tested: Yes

Palbociclib–Letrozole: CBR 84.3% (95% CI 80.0–88.0) Placebo–Letrozole: CBR 70.8% (95% CI 63.3–77.5) Comparison: OR 2.23 (95% CI 1.39–3.56; P<0.001)

Duration of Response — All Randomly Assigned Patients

Analysis population: Intention-to-treat (N=666)

Palbociclib–Letrozole: Median DoR 22.5 months (95% CI 19.8–28.0) Placebo–Letrozole: Median DoR 16.8 months (95% CI 14.2–28.5)

Duration of Response — Patients with Measurable Disease

Analysis population: Patients with measurable disease

Palbociclib–Letrozole: Median DoR 22.5 months (95% CI 19.8–28.0) Placebo–Letrozole: Median DoR 16.8 months (95% CI 15.4–28.5)

PFS by Blinded Independent Central Review (Supportive Analysis)

Analysis population: Intention-to-treat (N=666) Formally tested: No — this was a supportive analysis

Palbociclib–Letrozole: Median PFS 30.5 months (95% CI 24.7 to not estimable) Placebo–Letrozole: Median PFS 19.3 months (95% CI 16.4–30.6) Comparison: HR 0.65 (95% CI 0.51–0.84; two-sided P=0.001)

The central review PFS was consistent with and numerically larger than the investigator-assessed result, supporting the primary analysis.

Safety

Safety Population

Palbociclib–Letrozole: n=444; Placebo–Letrozole: n=222

Safety Summary

Grade 3 overall, grade 4 overall, grade 5 overall, treatment-related AE rates, and dose interruption rates were not reported as aggregate summary metrics in this publication. Table 2 reported individual AEs by grade 3 and grade 4 separately, but no aggregate "grade ≥3 any AE" row was provided.

Grade 3 or 4 Adverse Events of Clinical Significance

The grade specification (grade 3, grade 4, or grade 3 or 4) is reported as stated in the source publication. For hematologic AEs, the text reports combined "grade 3 or 4" rates; for fatigue and asthenia, only grade 3 was reported in Table 2. No grade 3 or 4 nonhematologic events occurred in more than 2.5% of patients in the palbociclib arm.

Adverse Events of Special Interest

Febrile Neutropenia

• Any grade / Grade 3 or 4: 1.8% palbociclib vs 0% placebo (8 patients)
• Clinical implication: Despite the very high rate of grade 3/4 neutropenia, febrile neutropenia was rare. The 1-week-off dosing schedule allows for hematologic recovery and likely contributes to the low febrile neutropenia rate.

Pulmonary Embolism

• Any grade: 0.9% palbociclib vs 1.4% placebo
• Clinical implication: No increased VTE risk was observed with palbociclib in this trial.

Deaths

• Deaths during treatment period: 10 (2.3%) palbociclib–letrozole vs 4 (1.8%) placebo–letrozole
• Treatment-related deaths: 0 in palbociclib arm; 1 in placebo arm (secondary to lower respiratory tract infection and pulmonary embolism, considered related to study regimen)

Subgroup Analyses

The PFS benefit of palbociclib plus letrozole was consistent across all prespecified subgroups. All point estimates favored palbociclib. Several subgroups showed particularly pronounced benefit: bone-only disease (HR 0.36; 95% CI 0.22–0.59), non-measurable disease (HR 0.35; 95% CI 0.22–0.57), lobular carcinoma (HR 0.46; 95% CI 0.26–0.78), and Asian patients (HR 0.48; 95% CI 0.27–0.87).

Interaction p-values were not reported for any subgroup comparison.

These subgroup analyses were prespecified and were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating.

Key Comparator Trials

Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.

Contextual Notes

PALOMA-2, MONALEESA-2 [4], and MONARCH 3 [5] together established CDK4/6 inhibitor plus aromatase inhibitor as the standard first-line endocrine-based therapy for postmenopausal women with HR+/HER2− advanced breast cancer. All three trials showed substantial PFS improvements. No head-to-head comparison exists among the three regimens.

The three CDK4/6 inhibitors have distinct safety profiles and dosing schedules. Palbociclib has a 3-weeks-on/1-week-off schedule with neutropenia as its principal toxicity; ribociclib has a similar intermittent schedule but carries a QTc prolongation signal requiring ECG monitoring; abemaciclib is administered continuously with diarrhea as the dominant toxicity. Subsequent OS analyses from these trials have been reported, and the choice among CDK4/6 inhibitors in clinical practice is informed by toxicity profile, patient comorbidities, subsequent data, and practical considerations.

PALOMA-2 was the first of these phase 3 trials to report, and palbociclib was the first CDK4/6 inhibitor approved for this indication. The trial confirmed the findings of the phase 2 PALOMA-1 study that led to accelerated FDA approval.

Grey Zones and Unanswered Questions

• Overall survival: OS data were immature at this publication. Whether the PFS benefit translates to a survival advantage was the critical open question. Subsequent analyses have been reported but were not part of this publication.

• Premenopausal women: PALOMA-2 enrolled only postmenopausal women. The applicability of palbociclib plus aromatase inhibitor to premenopausal women (with ovarian suppression) was not addressed by this trial. Other trials (e.g., MONALEESA-7) have addressed premenopausal patients.

• Biomarker-driven patient selection: No molecular biomarker (e.g., Rb expression, cyclin D1 amplification, PIK3CA mutation) was used for patient selection beyond ER+/HER2−. The trial does not identify which patients derive the most or least benefit from CDK4/6 inhibition, beyond the standard clinical subgroups analyzed.

• Post-progression therapy and sequencing: Subsequent therapy rates were not reported. The trial does not inform how to treat patients after progression on palbociclib plus letrozole — specifically, whether to use a different CDK4/6 inhibitor, switch endocrine backbone, or add a targeted agent.

• Patients with visceral crisis: Patients with advanced, symptomatic visceral spread at risk for life-threatening complications were excluded. PALOMA-2 does not address whether CDK4/6 inhibitor–based therapy can substitute for chemotherapy in this urgent clinical scenario.

Clinical Implications

Where This Fits in the Treatment Sequence

PALOMA-2 established palbociclib plus letrozole as first-line therapy for postmenopausal women with ER+/HER2− advanced breast cancer who have not received prior systemic therapy for advanced disease. This includes patients with newly diagnosed metastatic disease and those whose disease recurred after adjuvant therapy (provided they are not resistant to nonsteroidal aromatase inhibitors). Per NCCN guidelines [3], CDK4/6 inhibitor plus aromatase inhibitor is a Category 1 preferred first-line regimen.

Practical Considerations

• Dosing: Palbociclib 125 mg once daily, 3 weeks on / 1 week off, with letrozole 2.5 mg daily continuously. The intermittent schedule allows hematologic recovery.
• Dose modifications: Dose reduction required in 36.0% of patients. Per prescribing information [2], dose reductions: 125 mg → 100 mg → 75 mg. Permanent discontinuation of palbociclib alone (continuing letrozole) occurred in 33 patients (7.4%).
• Hematologic monitoring: CBC required before each cycle and on day 15 of first 2 cycles [2]. Despite very high neutropenia rates, febrile neutropenia was rare (1.8%), and no neutropenia-related deaths occurred in the palbociclib arm.
• Relative dose intensity: 93% for palbociclib — high adherence to the planned dose despite frequent neutropenia, reflecting the manageable nature of the intermittent dosing schedule.

Unanswered Questions

The two most practice-relevant open questions from this publication are: (1) whether the PFS benefit translates to an OS advantage, and (2) whether biomarkers can identify patients who derive exceptional or minimal benefit from CDK4/6 inhibition to optimize treatment selection.

Post-Progression Options

Subsequent therapy rates were not reported in this publication. In the current treatment landscape, second-line options after progression on CDK4/6 inhibitor plus aromatase inhibitor include CDK4/6 inhibitor plus fulvestrant (if not previously used), PI3K inhibitor (alpelisib for PIK3CA-mutated tumors), mTOR inhibitor (everolimus), other endocrine agents, antibody-drug conjugates, and chemotherapy.

Regulatory and Guideline Status

Regulatory

• FDA: Palbociclib (Ibrance) is FDA-approved in combination with an aromatase inhibitor as initial endocrine-based therapy for HR-positive, HER2-negative advanced or metastatic breast cancer in adult patients, and in combination with fulvestrant for disease progression on prior endocrine therapy. The first-line combination approval was based on PALOMA-2 [2].
• EMA: Approved for the same indication.

⚠️ Regulatory status verified as of March 2026. Confirm current approval status and labeled indications before clinical use at FDA.gov.

Guidelines

• NCCN: CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) plus aromatase inhibitor is a preferred first-line regimen for HR+/HER2− advanced breast cancer (Category 1) [3].

Companion Diagnostics

No companion diagnostic is required for the PALOMA-2 indication. ER positivity and HER2 negativity are assessed by standard immunohistochemistry and/or in situ hybridization per ASCO/CAP guidelines.

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.

Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.

All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.

Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.

Comparator trial data presented in the Key Comparator Trials section are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.

References

1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925-1936. doi:10.1056/NEJMoa1607303
2. Ibrance (palbociclib) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748. doi:10.1056/NEJMoa1609709
5. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646. doi:10.1200/JCO.2017.75.6155